文拉法辛缓释剂与SSRTs治疗难治性抑郁症对照研究.docVIP

文拉法辛缓释剂与SSRTs治疗难治性抑郁症对照研究 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：文拉法辛缓释剂与SSRTs治疗难治性抑郁症对照研究 1 1 对象与方法 3 2 结果 4 3 讨论 5 文2：文拉法辛缓释剂治疗难治性抑郁症的疗效观察 6 1 临床资料 6 2 结果 7 3 讨论 8 参考文摘引言： 9 原创性声明（模板） 10 文章致谢（模板） 11 正文 文拉法辛缓释剂与SSRTs治疗难治性抑郁症对照研究 文1：文拉法辛缓释剂与SSRTs治疗难治性抑郁症对照研究 Control study of venlafaxine and SSRIs in the treatment of refractory depression 【Abstract】 Objective To explore the clinical curative effect and safety of venlafaxine in refractory depression. Methods 60 patients with refractory depression were randomly divided into study (venlafaxine) and control group(SSRIs) for 12 months. Before treatment and at the ends of 1st, 3rd, 6th and 12th month of treatment, the clinical curative effects were assessed with the Hamilton Depression Scale (HAMD), advee effects with the Treatment Emergent Symptom Scale(TESS) and quality of life with the WHO Quality of Life(WHOQOL). Results At the end of 1st month , scores of the HAMD decreased significantly or very significantly for both the two groups compared with pretreatment(P or ),in corresponding period those of the research group did more significantly compared with the control group(P). At the end of 1st month, scores of the WHOQOL increased significantly or very significantly for both the two groups compared with pretreatment(P or ), in corresponding period scores of psycho domain, social relatiohip and environmental factor did more significantly in the research group compared with the control group(P or ).The advee effects of both groups were mild, and there were significant differences in dry mouth, hyperhidrosis, cotipation between the two groups(P). Conclusion Venlafaxine is better than SSRIs in the treatment of depression, can notably improves patients’ quality of life, and has higher safety and better compliance. 【Keywords】 Refractory depression; venlafaxine; SSRIs; quality of life; the HAMD 难治性抑郁症的治疗方法很多，但疗效均不理想。文拉法辛缓释剂（商品名：贻诺思）为新型抗抑郁剂，主要通过抑制5羟色胺（5HT）和去甲肾上腺素（NE）的再摄取发挥抗抑郁效应。为探讨文拉法辛缓释剂治疗难治